Halozyme Therapeutics Raises 2026 Revenue Outlook After Q3 Beat

Third-quarter revenue rose 39% year over year to $493 million, while non-GAAP earnings per share reached $2.39, 3 cents above estimates.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.